

# LEUKEMIA2020-2021

Rome, Hotel NH Collection Vittorio Veneto April 26-27, 2021

Coordinator: A.M. Carella AlL President: S. Amadori



UNDER THE AUSPICES OF:







# LEUKEMIA2020-2021

Rome, Hotel NH Collection Vittorio Veneto April 26-27, 2021

## Welcome message

We welcome you to the 10th annual Conference on "Leukemia 2020-2021". We are very pleased to inform you that the Conference will be held in cooperation with the Italian Association against Leukemia, Lymphomas and Myeloma (AIL), the largest Italian voluntary organization dedicated to funding blood cancer research and patient services. The aim of the Conference is to bring together highly qualified Italian and international scientists and clinicians to discuss emerging paradigms and breakthroughs at the forefront of biology and treatment across the spectrum of blood cancers, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative disorders, lymphomas and myelomas. Attendees will hear of recent findings in basic and clinical research, from the molecular basis of blood cancers to novel therapies emerging in the clinic, through ample interaction with key experts in the field.

### **SERGIO AMADORI**

**AIL President** 

for the

### **ANGELO MICHELE CARELLA**

Scientific Coordinator LEUKEMIA 2020-2021

### **SCIENTIFIC BOARD**

Sergio Amadori
Angelo M. Carella
Fabio Ciceri
Antonio Cuneo
Fabrizio Pane
Alessandro Rambaldi
Valeria Santini
Alessandro M. Vannucchi

### **AIL SCIENTIFIC COMMITTEE**

William Arcese Fabrizio Pane Pier Giuseppe Pelicci Francesco Rodeghiero Giorgina Specchia



### Faculty

racony		
Sergio Emanuele Michele Renato Andrea Francesc Massimo Angelo Michele Michele Sabina Fabio Paolo	AMADORI ANGELUCCI BACCARANI BASSAN BIONDI BOSCH BRECCIA CARELLA CAVO CHIARETTI CICERI CORRADINI	Rome, Italy Genoa, Italy Bologna, Italy Mestre (VE), Italy Monza (MB), Italy Barcelona, Spain Rome, Italy Genoa, Italy Bologna, Italy Rome, Italy Milan, Italy Milan, Italy
Antonio	CUNEO	Ferrara, Italy
Matteo G. Fabio	DELLA PORTA EFFICACE	Rozzano (MI), Italy Rome, Italy
Robin	FOÀ	Rome, Italy
Paolo	GHIA	Milan, Italy
Paola	GUGLIELMELLI	Florence, Italy
llaria	IACOBUCCI	Memphis, USA
Alessandro	ISIDORI	Pesaro, Italy
Roberto M.	LEMOLI	Genoa, Italy
Francesco	MANNELLI	Florence, Italy
Giovanni	MARTINELLI	Meldola (FC), Italy
Francesca R.	MAURO	Rome, Italy
Marco	MONTILLO	Milan, Italy
Pellegrino	MUSTO	Bari, Italy
Esther N.	OLIVA	Reggio Calabria, Italy
Fabrizio	PANE	Naples, Italy
Francesco	PASSAMONTI	Varese, Italy
Giovanni	PIZZOLO	Verona, Italy
Uwe	PLATZBECKER	Leipzig, Germany
Alessandro	RAMBALDI	Bergamo, Italy
Gianantonio	ROSTI	Bologna, Italy
Philippe	ROUSSELOT	Le Chesnay, France
Nigel	RUSSELL	Nottingham, UK
Giuseppe	SAGLIO	Orbassano (TO), Italy
Valeria	SANTINI	Florence, Italy
Simona	SICA	Rome, Italy
Sergio	SIRAGUSA	Palermo, Italy
Radek C.	SKODA	Basel, Switzerland
Simona Luca A.E.	SOVERINI VAGO	Bologna, Italy Milan, Italy
Alessandro M.	VANNUCCHI	Florence, Italy
Adriano	VANNUCCHI VENDITTI	Rome, Italy
Marco	VIGNETTI	Rome, Italy
Umberto	VITOLO	Candiolo (TO), Italy
Maria Teresa	VOSO	Rome, Italy
Pier Luigi	ZINZANI	Bologna, Italy
i ioi Loigi	Z11 1Z/ 11 11	bologila, naiy

# Monday, April 26, 2021

11.00 am	Opening Ceremony	S. Amadori	, A.M. Carella
11.15 am	Clinical advances in hematologic mali paving the way for better quality of life of Introduced by M. Vignetti	_	F. Efficace
SESSION I	ACUTE MYELOID LEUKEMIA Chairman: S. Amadori		
11.30 am 11.45 am 12.00 pm 12.15 pm 12.30 pm 12.45 pm	Practice-changing treatments Emerging molecularly-targeted therape Novel approaches to targeted epigenetic Clinical use of MRD testing Recent developments in immunothera	therapy	N. Russel G. Martinelli S. Sica A. Venditti A. Isidori
01.00 pm	Light Lunch		
SESSION II	MYELODYSPLASTIC SYNDROMES Chairmen: P. Musto, V. Santini		
01.45 pm 02.00 pm 02.15 pm 02.30 pm 02.45 pm 03.00 pm	Relevance of molecular characterization prognostic stratification and choice of Targeted therapy in low risk MDS Novel therapies in high risk MDS Relevance of quality of life and patient outcome in designing therapeutic strategy Transplant options in 2019  Discussion	therapy reported	M.G. Della Porta U. Platzbecker M.T. Voso E.N. Oliva E. Angelucci
03.00 pm	Discussion		

SESSION III	MYELOPROLIFERATIVE NEOPLASMS Chairman: A.M. Vannucchi	
03.15 pm 03.30 pm 03.45 pm 04.00 pm 04.15 pm	The stem cell of MPN  Balancing toxicity and efficacy of JAK2 inhibitors  Managing loss of response to ruxolitinib  Unusual thrombosis  Mutations and target treatment in systemic mastocytosis	R.C. Skoda F. Passamonti P. Guglielmelli S. Siragusa
04.30 pm	Discussion	r. Marinelli
04.45 pm	Coffee Break	
05.00 pm	JOHN GOLDMAN LECTURE Introduced by A.M. Carella	M. Baccarani
SESSION IV	CHRONIC MYELOID LEUKEMIA Chairman: F. Pane	
05.30 pm 05.45 pm	Ph+ stem cells and marrow microenvironment Patient management before and during	S. Soverini
06.00 pm 06.15 pm 06.30 pm	treatment-free remission Guidelines 2020 Future perspectives of novel therapies Atypical chronic myeloid leukemia	P. Rousselot G. Rosti G. Saglio M. Breccia

06.45 pm

Discussion

# Tuesday, April 27, 2021

SESSION V	ACUTE LYMPHOBLASTIC LEUKEMIA Chairman: A. Rambaldi		
08.30 am 08.45 am	New insights in the biology of ALL MRD-driven strategy in Ph-like ALL: doe	s it work?	I. lacobucci S. Chiaretti
09.00 am	Current treatment strategies in Ph+ ALL		R. Foà
09.15 am	Current treatment strategies in T-ALL		R. Bassan
09.30 am	CAR-T in pediatric and adult patients		A. Biondi
09.45 am	Discussion		
10.00 am	Coffee Break		
SESSION VI	CHRONIC LYMPHOCYTIC LEUKEMI Chairmen: A. Cuneo, G. Pizzolo	IA	
10.15 am	Prognostic/predictive factors in		
	the target treatment era		F. Bosch
10.30 am	The standard of care in CLL: new guide		P. Ghia
10.45 am	Treatment with novel drugs: until progre	ession?	ED 14
	- Yes - No		F.R. Mauro M. Montillo
11.15 am	Discussion		W. WOITING
11.13 dili	Discussion		
SESSION VII	NOVEL IMMUNOTHERAPIES Chairmen: F. Ciceri, U. Vitolo		
11.30 am	Bites and darts in hematological maligraturent options	nances:	R.M. Lemoli
11.45 am	New recombinant antibodies in lympho	omas	P.L. Zinzani
12.00 pm	CAR-T in lymphomas	J111G3	P. Corradini
12.15 pm	CAR-T in MM		M. Cavo
12.30 pm	CAR-T in AML		L.A.E. Vago
12.45 pm	Discussion		
01.00 pm	Closing Remarks	S. Amadori,	, A.M. Carella

### **GENERAL INFORMATION**

### **MEETING VENUE**

NH Hotel Vittorio Veneto Corso d'Italia, 1 - 00198 Rome, Italy Phone +39 06 84951

### OFFICIAL LANGUAGE

The meeting will be in English.

No simultaneous translation will be provided.

### REGISTRATION

The registration is free. It is possible to register on the website www.ercongressi.it, section Congressi/2021.

### **BADGE and CERTIFICATE OF ATTENDANCE**

All registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.

### **ITALIAN CME CREDITS**

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-282400.
- No. **7,7 CME** credits for Physicians (disciplines: Hematology, Oncology) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

### **CHANGES**

Parts of the program may be changed without notice.

### **ORGANIZING SECRETARIAT**

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy Ph +39 051 4210559 - Fax +39 051 4210174

E-mail: ercongressi@ercongressi.it

www.ercongressi.it